NSAID Use Survival Link Varies With KRAS Status in CRC Patients
Use of NSAIDs tied to better survival for colorectal cancer survivors with KRAS wild-type tumors
TUESDAY, June 20, 2017 (HealthDay News) -- Regular use of nonsteroidal anti-inflammatory drugs (NSAIDs) is associated with improved survival among colorectal cancer (CRC) survivors with KRAS wild-type tumors, according to a study published online June 15 in the Journal of Clinical Oncology.
Xinwei Hua, M.P.H., from the Fred Hutchinson Cancer Research Center in Seattle, and colleagues administered detailed epidemiologic questionnaires to 2,419 patients age 18 to 74 years with incident invasive CRC, diagnosed from 1997 to 2008.
The researchers observed 381 deaths after a median of 10.8 years of follow-up since diagnosis. Post-diagnostic aspirin-only users had more favorable overall survival (OS) and CRC-specific survival (hazard ratios, 0.75 [95 percent confidence interval, 0.59 to 0.95] and 0.44 [95 percent confidence interval, 0.25 to 0.71], respectively), compared with nonusers; the findings were more pronounced among those who initiated aspirin use (hazard ratios, 0.64 [95 percent confidence interval, 0.47 to 0.86] and 0.40 [95 percent confidence interval, 0.20 to 0.80], respectively). There was significant variation in the correlation between any NSAID use after diagnosis and OS with KRAS-mutation status (Pinteraction = 0.01). NSAID use after diagnosis correlated with OS among those with KRAS wild-type tumors (hazard ratio, 0.60 [95 percent confidence interval, 0.46 to 0.80]), but not for those with KRAS-mutant tumors (hazard ratio, 1.24 [95 percent confidence interval, 0.78 to 1.96]).
"Among long-term CRC survivors, regular use of NSAIDs after CRC diagnosis was significantly associated with improved survival in individuals with KRAS wild-type tumors," the authors write.
Several authors disclosed financial ties to the biopharmaceutical industry.